Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing.

about

Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies.

P2860

Q33882864-968FD013-434C-4512-8293-0150186D9182 Q52645038-A0E105F8-81EF-4C94-A0C6-D014D15F04FE

P2860

Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing.

Item

http://www.wikidata.org/entity/Q42381432

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing.

@en

Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing.

@nl

type

Item

label

Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing.

@en

Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing.

@nl

prefLabel

Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing.

@en

Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing.

@nl

P1476

Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing.

@en

P2093

Eric B Haura

http://www.w3.org/2001/XMLSchema#string

Uwe Rix

http://www.w3.org/2001/XMLSchema#string

P2860

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

P31

scholarly article

editorial

P356

10.1093/JNCI/DJU250

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265611264

http://www.w3.org/2001/XMLSchema#string

P698

25214562

http://www.w3.org/2001/XMLSchema#string

P932

5072366

http://www.w3.org/2001/XMLSchema#string

Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing.

about

P2860

P2860

Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P577

P5875

P698

P932